Nestlé Health Science and Seres Therapeutics Inc. signed a contract
In July 2021, SER-109, an experimental oral microbiome treatment for recurrent Clostridioides difficile infection (CDI), will be jointly marketed in the United States (U.S.) and Canada by Seres Therapeutics Inc. and Nestlé Health Science. The first ever microbiome therapy to receive FDA approval would be SER-109.
Advancement in Technology to Accelerate Market Growth
One significant trend that is becoming increasingly popular in the human microbiome industry is the expanding use of technology. Leading businesses in the human microbiome industry are concentrating on creating cutting-edge technological solutions for microbiomes. For instance, Probiotic and Prebiotic Daily Synbiotic for both genders has been made available by Seed, a new microbiome startup. The Daily Synbiotic Seed is the first product that employs a microbe-system technique with strain-specific benefits beyond digestive health, including cardiovascular safety, dermatological health, immunological control, reproductive health, gut barrier integrity, and oxidative stress.
Growth Of The Market Is Constrained By Difficulties In Establishing The Relationship Between Dysbiosis And Illnesses
The microbiota, a complex mix of commensal, pathogenic, and symbiotic bacteria, lives inside the human body. Just 30–40 species of the microbiota are shared by individuals, according to several research. Identifying specific bacteria from among trillions of species can be a tremendously tough undertaking. High-throughput omics technology can identify the particular bacterial species involved and provide an understanding of how balance between humans and microorganisms is maintained. Research on the human microbiome suggests that several of the most common chronic and lifestyle diseases, including obesity, diabetes, and a variety of digestive ailments, are caused by dysbiosis of the microbiomes. Comparisons with parallel control groups of healthy individuals are necessary for the existing methods for finding microbial markers for diagnostic reasons. It can be difficult to determine which microbe is most suited for a certain application, making it difficult to choose the proper microbial chassis for a microbiota-based treatment.
Major Players Develop Acquisition Plans to Boost Brand Image
The leading businesses in the human microbiome market plan acquisitions to improve their brand recognition globally. For instance, in July 2021, pre-clinical research on the second-generation immuno-oncology LBP MRx1299, which is increasing the activity of CAR-T, has been published, according to 4D pharma plc, a pharmaceutical company leading the development of Live Bio medicinal. It shows how, in animal cancer models, the bacterium Megasphaera massiliensis or its short chain fatty acid (SCFA) metabolite pentanoate might improve tumour clearance by enhancing the anti-tumor activity of cytotoxic T lymphocytes (CTL) and CAR-T treatments.
- In June 2021, an innovative ex-vivo research and discovery platform called NovoSift is being developed by NovoBiome, a drug development business, to study the symbiotic link between the microbiota and the human intestine.
List of Key Players Profiled in the Report
- ENTEROME (France)
- Yakult (US)
- DuPont (US)
- Metabiomics Corporation (US)
- ViThera Pharmaceuticals, Inc. (US)
- Second Genome Inc. (US)
- MICROBIOME THERAPEUTICS LLC (US)
- Vedanta Biosciences, Inc. (US)
- Osel, Inc. (US)
- Merck Sharp & Dohme Corp (Germany)
- Seres Therapeutics (US)
- Synthetic Biologics, Inc. (US)
- Synlogic (US)
- 4D pharma plc (UK)
- Metabogen AB (Sweden)
- Ritter Pharmaceuticals (US)
- Symberix (US)
- Symbiotix Biotherapies, Inc. (US)
Further Report Findings
- The market in North America is expected to gain a huge portion of the global Human microbiome market share in the coming years because there is a solid foundation of healthcare facilities, more money is being invested by big businesses in developing cutting-edge technologies, and more research is being done in this area.
- Rising incidence of lifestyle diseases, an emphasis on human microbiome therapeutics, and increasing technology developments in next-generation sequencing and the human microbiome are all contributing to the market's growth.
- In the Europe, the growth in this region is primarily driven by increasing government measures to raise awareness and regional research activities.
|Market Size in 2022
|USD 245.1 Billion
|Market Forecast in 2030
|USD 1579.9 Billion
|Compound Annual Growth Rate
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product, By Disease, By Application, By Type, By Technology and By Geography